Company Listing
SFJ Pharmaceuticals - SFJ-NSCLC

SFJ-NSCLC and Pfizer are conducting a late-stage trial of Pfizer's potential non-small cell lung cancer (NSCLC) treatment dacomitinib. Usually drugs are launched in Japan and Asia several years after they have been launched in the US and other developed countries, limiting the therapeutic options available to physicians and patients. SFJ-NSCLC intends to reduce this delay.

 

BACK
Location
Pleasanton, California
CEO
Robert DeBenedetto
Abingworth Partner
Ken Haas
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

SFJ-NSCLC and Pfizer are conducting a late-stage trial of Pfizer's potential non-small cell lung cancer (NSCLC) treatment dacomitinib. Usually drugs are launched in Japan and Asia several years after they have been launched in the US and other developed countries, limiting the therapeutic options available to physicians and patients. SFJ-NSCLC intends to reduce this delay.

 

Location
Pleasanton, California
CEO
Robert DeBenedetto
Abingworth Partner
Ken Haas
Website Address
BACK
 
Copyright Abingworth 2017